The role of dynamic monitoring of plasma cell-free DNA methylation in predicting pathological response in resectable stage IIB-IIIB non-small cell lung cancer: biomarker analyses from a prospective phase II trial.

BMC Med · 2025 · PMC12587505 · PMID 41194150

Europe PMC DOI

hedged sentence

0.0540

closest p · 1.1× alpha

0.0540

boldest claim

The sentences

marginally significantP = 0.054so close (0.05 < p ≤ 0.1)

Additionally, patients with PD-L1 positive (TPS ≥ 1%) had a higher pCR rate (nominal P = 0.025) and a marginally significant higher MPR rate (nominal P = 0.054).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.